Mayo Clinic work shows possible Lucentis side effect

ByConnor Hodde

At the Amercian Academy of Opthalmology 115th Annual Meeting, findings were presented from a retrospective study conducted after a Mayo Clinic opthalmologist noticed an increase in intraoccular pressure (IOP) in her patients using Genentech’ (Roche) Lucentis (ranibizumab), an FDA-approved drug for the treatment of age-related macular degeneration (AMD).

MARINA (Minimally Classic/OccultTrial of the Anti-Vascular Endothelial Growth Factor Antibody Ranibizumab in the Treatment of Neovascular Endothelial Age-Related Macular Degeneration) and ANCHOR (Anti-VEGF antibody for the treatment of predominantly classic Choroidal Neovascularization in Age-Related Macular Degeneration) evaluated drugs, including ranibizumab, for the treatment of AMD and other forms of MD.

http://www.bioopticsworld.com/news/2011/10/1530123521/mayo-clinic-work-shows-possible-lucentis-side-effect.html

Similar Posts

Retina Protein That May Help Conquer Blindness Discovered

ByConnor Hodde

Research led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the LSU Health New Orleans Neuroscience Center of Excellence, discovered a protein in the retina that is crucial for vision. The paper reports, for the first time, the key molecular mechanisms leading to visual degeneration and blindness. The research reveals events that may…

EyeCRO conducts successful pre-IND meeting with US Food and Drug Administration to discuss CsA-MIDROPS™

ByPhotoreceptor

EyeCRO recently requested and conducted a pre-IND meeting with the US FDA to discuss the nonclinical and clinical development plans for CsA-MiDROPS™ to treat Dry Eye Disease. The agency was supportive of the project and agreed that the proposed nonclinical and CMC studies would allow entry into a phase II clinical trial. Also discussed was…

EyeCRO scientist contributes to a paper published in Experimental Eye Research

ByConnor Hodde

EyeCRO scientist Jarrod Harman contributed to a paper focused on X-linked juvenile retinoschisis published in Experimental Eye Research. This paper expands the mechanistic understanding of XLRS. Read the full paper here https://www.sciencedirect.com/science/article/pii/S0014483523002129?dgcid=coauthor

Biodegradable nanoparticles slip through mucus

ByConnor Hodde

Researchers at Johns Hopkins University (JHU) have created biodegradable, ultra tiny, nanosized particles that can easily slip through the body’s sticky and viscous mucus secretions to deliver a sustained-release medication cargo. The interdisciplinary team of researchers, led by Justin Hanes of the JHU Center for Nanomedicine, developed the nanoparticles so that they not only penetrate…

eyecro’s First Published Article in Molecular and Cellular Biology

ByConnor Hodde

Retinol-Binding Protein 4 Induces Inflammation in Human Endothelial Cells by a NADPH Oxidase- and Nuclear Factor Kappa B-dependent and Retinol-Independent Mechanism  Krysten M. Farjoa,#,    Rafal A. Farjob,    Stacey Halseya,    Gennadiy Moiseyeva and    Jian-xing Maa  aDepartment of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma beyecro LLC, Oklahoma City, Oklahoma ABSTRACT Serum retinol-binding protein…